Latest news with #LYRA
Sunday World
2 days ago
- Entertainment
- Sunday World
Lyra teams up with Grammy-nominated writer for electricfying new single
NEW ERA | 'She, he, they, them—whatever your category, you're one of us. And in my world, that means you're iconic.' The Cork-born pop queen describes the electrifying single, Weird Club, as 'a bold and unapologetic anthem celebrating self-expression, individuality and unity.' Lyra and Krantz, who has worked with the likes of Ed Sheeran and has had her songs covered by superstars from Geri Halliwell to Cliff Richard, tell how the song invites everyone to join the club where being different is the ultimate power. Bursting with energy, shimmering synths, and Lyra's powerhouse vocals, the track offers an open invitation to 'the world's misfits, dreamers and originals'. Lyra Today's News in 90 Seconds - June 13 2025 Lyra says: 'She, he, they, them—whatever your category, you're one of us. And in my world, that means you're iconic.' A proud ally and fearless advocate for inclusion, Lyra continues to use her platform to champion authenticity and celebrate difference. With Weird Club, she blends powerful pop with a message that's deeply personal and globally relevant: there is beauty in every kind of identity, and strength in standing proud. After an unforgettable 2024 that saw Lyra's debut album LYRA hit number one and her sold-out tour light up stages across Ireland, Weird Club signals the start of a fearless new era. Proving that she's up for any challenge, Lyra recently teamed up with former Taoiseach Leo Varadkar and special forces veteran Ray Goggins on the gritty TV travel series Uncharted. Filmed in the breathtaking Drakensberg Mountains of South Africa, the series revealed a new side to Lyra as she pushed her boundaries, both physically and emotionally, against one of the world's most rugged landscapes. As part of their gruelling challenge, the trio slept in caves, scaled mountains and climbed sheer rock faces on their way to the summit of Tugela Falls, one of the tallest waterfalls in the world. However, Lyra admits that her biggest challenge is coping with the endless negativity she experiences from the 'keyboard warriors' on social media. She says: 'They love to take you down a peg or two. They love to be keyboard warriors. I am a people pleaser and I like making people happy, and then when people message me, taking me down, I feel like I've not reached the bar I should have reached, and I'm not good enough and it gets me in the heart. I always get upset when I talk about it.' Looking back on the early days of her career, Lyra recalled how industry chiefs put her under pressure to lose weight – and it triggered her bulimia. She says she regrets 'not standing up and saying, 'This is me – accept it or not,' adding: 'I wish I had done it sooner, because I would have gotten a lot more of my life back and enjoyed my first experiences in the music industry a lot better.' Insecurity is still a personal issue that Lyra has to occasionally grapple with. 'I get up on stage wearing half nothing, flailing around with my arse out and yet I'm so insecure,' she says. However, Lyra credits her manager Caroline Downey – also the manager of Hozier - with giving her the confidence to pursue her dream of life as a songwriter, singer and performer in the major league of the music business.. 'When I met Caroline Downey my life changed,' Lyra told Shuffle. 'She's an inspiration. I feel like that's when I became me. She said she saw something in me that she had seen in Andrew (Hozier), which is a massive compliment as I'm a massive fan of Hozier. 'I felt accepted for the first time. I felt, 'ok, I'm good enough now'…and that's when I feel that I really truly became a great artist, because I didn't have to pretend anymore. Why I write about relationships a lot is because that is what I was looking for in relationships.'
Yahoo
02-06-2025
- Business
- Yahoo
Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win
June 2 - Shares of Lyra Therapeutics (NASDAQ:LYRA) soared more than 500% on Monday after the company reported encouraging Phase 3 results for its sinus implant treatment, LYR-210. Warning! GuruFocus has detected 6 Warning Signs with LYRA. The ENLIGHTEN 2 study met its primary goal, showing statistically significant improvement in chronic rhinosinusitis (CRS) symptoms at 24 weeks. The therapy helped reduce nasal obstruction, discharge, and facial pressure, with a p-value of 0.0078. Lyra also reported success on key secondary endpoints. These included improvements in broader symptom scores and patient quality-of-life measures, such as the SNOT-22 index. Benefits were observed from week 4 and sustained over the 6-month trial. The safety profile was comparable to the sham group. The company also shared findings from a combined analysis of patients with nasal polyps from both ENLIGHTEN 1 and 2 trials. While not all results reached statistical significance, multiple efficacy signals were noted. Lyra plans to engage the U.S. Food and Drug Administration on a possible New Drug Application for patients without nasal polyps and may expand trials to include polyp patients. The stock jump reflects investor optimism around LYR-210's potential to become a long-acting option for CRS patients who don't respond to standard treatments. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
02-06-2025
- Business
- Yahoo
Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win
June 2 - Shares of Lyra Therapeutics (NASDAQ:LYRA) soared more than 500% on Monday after the company reported encouraging Phase 3 results for its sinus implant treatment, LYR-210. Warning! GuruFocus has detected 6 Warning Signs with LYRA. The ENLIGHTEN 2 study met its primary goal, showing statistically significant improvement in chronic rhinosinusitis (CRS) symptoms at 24 weeks. The therapy helped reduce nasal obstruction, discharge, and facial pressure, with a p-value of 0.0078. Lyra also reported success on key secondary endpoints. These included improvements in broader symptom scores and patient quality-of-life measures, such as the SNOT-22 index. Benefits were observed from week 4 and sustained over the 6-month trial. The safety profile was comparable to the sham group. The company also shared findings from a combined analysis of patients with nasal polyps from both ENLIGHTEN 1 and 2 trials. While not all results reached statistical significance, multiple efficacy signals were noted. Lyra plans to engage the U.S. Food and Drug Administration on a possible New Drug Application for patients without nasal polyps and may expand trials to include polyp patients. The stock jump reflects investor optimism around LYR-210's potential to become a long-acting option for CRS patients who don't respond to standard treatments. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
